Circulating insulin-like growth factor-i and prostate cancer risk

摘要

A method of predicting increased risk of prostate cancer in an individual without prostate cancer. It involves the measuring the concentration of insulin-like growth factor (IGF-I) in a body fluid from an individual. An elevated concentration of IGF above a reference range for IGF indicates an increased risk for prostate cancer in the future. Body fluid used may include blood, plasma, serum and seminal fluid. Additionally, the concentrations of IGF-I and insulin-like growth factor-1 (IGFB-3) are measured. A multivariate adjustment of IGF-I concentration relative to IGFB-3 provides an adjusted IGF-I level. Where such a level is above a reference range for adjusted IGF-I indicates an increased risk for prostate cancer in the future. A multivariate adjustment of the IGF-I concentration relative to the PSA concentration to provides an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for prostate cancer in the future with a poor prognosis. A multivariate adjustment of the IGF-I concentration relative to IGFBP and PSA concentrations to provide an adjusted IGF/PSA value. Where such a value is above the reference range for adjusted IGF/PSA indicates an increased risk for severe prostate cancer in the future. IGF-I concentrations are compared to a reference group without prostate cancer to establish a reference level.